Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
  • Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2
  • Approximately 140,000 Americans live with IPF, a rare disease with no cure, and 50,000 new cases are diagnosed annually3
  • Sandoz is committed to developing and providing patient access to high-quality, more affordable generic medicines, especially in areas of high unmet need

Princeton, May 12, 2022 — Sandoz, a global leader in …

/by
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Ad hoc announcement pursuant to Art. 53 LR

  • Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD)
    • Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating income +5% (cc, 0% USD)
    • Strong performance of key growth brands including Entresto, Kesimpta, Cosentyx and Zolgensma
    • Sandoz sales grew +8% (cc, +2% USD) and core operating income +26% (cc, +21% USD), benefiting from a lower prior year comparison as …
/by
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
  • Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1
  • Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pressure to build up3
     
  • Sandoz manufactures high-impact medicines that bring savings to US patients and support the sustainability of the overall US healthcare system

Basel, April 14, 2022 — Sandoz, …

/by
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

/by
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

/by
Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
  • Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics
  • Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide
  • Acquisition further demonstrates Sandoz commitment to pioneer access for patients

Basel, March 14, 2022 — Sandoz, a Novartis division, announced today that it has successfully acquired the UK-based medical and drug delivery device …

/by
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
  • Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4
  • Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2
  • Sandoz is committed to developing and providing generic oncology therapies, to provide patients access to affordable, high-quality …
/by
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LR

  • Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)
    • IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)
    • Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD)
  • Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance
    • Innovative Medicines (IM …
/by
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LR

  • Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)
    • IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)
    • Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD)
  • Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance
    • Innovative Medicines (IM …
/by
Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
  • Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.
     
  • Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new cases in 2020 in Europe alone1
     
  • Sandoz has been developing and providing oncology medicines for over 30 years, to expand access to and increase affordability of high quality medicines
     

Basel, December 22, 2021 — Sandoz, a global …

/by